Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Philip Serlin
|
| gptkbp:country |
gptkb:Israel
|
| gptkbp:focus |
immunology
oncology drug development |
| gptkbp:foundedYear |
2003
|
| gptkbp:headquartersLocation |
Modi'in Technology Park, Modi'in, Israel
|
| https://www.w3.org/2000/01/rdf-schema#label |
BioLineRx
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:Tel_Aviv_Stock_Exchange
|
| gptkbp:notableProduct |
motixafortide
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
BLRX
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.biolinerx.com/
|
| gptkbp:bfsParent |
gptkb:הר_חוצבים
|
| gptkbp:bfsLayer |
6
|